Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $193,390.74 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $16.47, for a total transaction of $193,390.74. Following the transaction, the insider now owns 159,782 shares in the company, valued at approximately $2,631,609.54. This represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded up $0.17 on Tuesday, reaching $16.59. The company’s stock had a trading volume of 795,172 shares, compared to its average volume of 553,834. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2.19 billion, a P/E ratio of -10.84 and a beta of 1.53. The stock has a 50-day moving average price of $16.80 and a 200-day moving average price of $14.97. Centessa Pharmaceuticals plc has a 52-week low of $7.38 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at about $20,698,000. Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after purchasing an additional 953,659 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after purchasing an additional 850,000 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its position in shares of Centessa Pharmaceuticals by 123.4% in the third quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company’s stock valued at $19,623,000 after purchasing an additional 677,966 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of several recent analyst reports. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.